Selvita S.A.

Warsaw Stock Exchange SLV.WA

Selvita S.A. Price to Sales Ratio (P/S) on January 14, 2025: 2.32

Selvita S.A. Price to Sales Ratio (P/S) is 2.32 on January 14, 2025, a -26.85% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Selvita S.A. 52-week high Price to Sales Ratio (P/S) is 3.75 on May 23, 2024, which is 61.61% above the current Price to Sales Ratio (P/S).
  • Selvita S.A. 52-week low Price to Sales Ratio (P/S) is 2.32 on January 14, 2025, which is 0.00% below the current Price to Sales Ratio (P/S).
  • Selvita S.A. average Price to Sales Ratio (P/S) for the last 52 weeks is 3.17.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Loading...
Warsaw Stock Exchange: SLV.WA

Selvita S.A.

CEO Mr. Boguslaw Stanislaw Sieczkowski M.B.A.
IPO Date Oct. 17, 2019
Location Poland
Headquarters ul. Bobrzynskiego 14
Employees 886
Sector Health Care
Industries
Description

Selvita S.A. operates as a contract research organization in Poland, rest of Europe, the United States, and internationally. It operates in two segments, Contract Research Organization (CRO) services, and Bioinformatics. The company offers drug discovery services in the areas of assay development and screening, medicinal and synthetic chemistry, computer-aided drug design/ artificial intelligence, structural biology, in vitro/ In Vivo pharmacology, ADME/DMPK and analytical testing. It also provides pharma services in the field of drug testing and bioanalytical analysis, including development and optimization, validation and transfer, stability studies, quality control, and regulatory aspects support services. In addition, the company offers research and development services in the areas of process research, laboratory scale custom synthesis of NCEs, industrial chemistry, and synthesis of isotopically labelled compounds, as well as other services for the agrochemical industry. Further, it provides bio-data science and advanced software services to data-driven life science and healthcare organizations. Selvita S.A. was founded in 2007 and is headquartered in Krakow, Poland.

Similar companies

MBR.WA

Mo-BRUK S.A.

USD 84.69

2.50%

NEU.WA

NEUCA S.A.

USD 204.85

1.34%

RVU.WA

Ryvu Therapeutics S.A.

USD 7.78

-9.75%

ACP.WA

Asseco Poland S.A.

USD 22.68

1.28%

KTY.WA

Grupa Kety S.A.

USD 165.64

1.04%

StockViz Staff

January 15, 2025

Any question? Send us an email